Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: rVIIa-FP
Biological: Placebo (0.9% normal saline)

First Posted Date: 2012-03-02

Last Posted Date: 2017-04-21

Lead Sponsor: CSL Behring

Target Recruit Count: 40

Registration Number: NCT01542619

Locations: 🇩🇪
Phase I Unit, Berlin, Germany

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)

Phase 1

Terminated

Conditions: Acute GvHD

Interventions: Biological: ALD518

First Posted Date: 2012-02-09

Last Posted Date: 2021-02-17

Lead Sponsor: CSL Behring

Target Recruit Count: 3

Registration Number: NCT01530256

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Loyola Medical Center, Maywood, Illinois, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 2 locations

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Phase 2

Completed

Conditions: Hemophilia B

Interventions: Biological: rIX-FP

First Posted Date: 2011-12-21

Last Posted Date: 2016-05-09

Lead Sponsor: CSL Behring

Target Recruit Count: 63

Registration Number: NCT01496274

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, Indiana, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 27 locations

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Phase 2

Completed

Conditions: Arthritis, Psoriatic

Interventions: Biological: Placebo matching BMS-945429
Biological: BMS-945429

First Posted Date: 2011-12-13

Last Posted Date: 2021-11-05

Lead Sponsor: CSL Behring

Target Recruit Count: 165

Registration Number: NCT01490450

Locations: 🇺🇸
San Diego Arthritis Medical Clinic, San Diego, California, United States
🇺🇸
Denver Arthritis Clinic, Denver, Colorado, United States
🇺🇸
New England Research Associates, Llc, Trumbull, Connecticut, United States

and more 9 locations

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Phase 2

Completed

Conditions: Hemophilia A

Interventions: Biological: rVIII-SingleChain
Biological: Octocog alfa

First Posted Date: 2011-12-07

Last Posted Date: 2016-08-09

Lead Sponsor: CSL Behring

Target Recruit Count: 175

Registration Number: NCT01486927

Locations: 🇬🇧
Study Site, London, United Kingdom

Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery

Phase 3

Completed

Conditions: Surgical Blood Loss
Postoperative Blood Loss

Interventions: Biological: Fibrinogen Concentrate (Human) (FCH)
Biological: Placebo

First Posted Date: 2011-11-21

Last Posted Date: 2014-09-18

Lead Sponsor: CSL Behring

Target Recruit Count: 152

Registration Number: NCT01475669

Locations: 🇦🇹
Allgemeines Krankenhaus der Stadt Wien - Universitätskliniken, Vienna, Austria
🇧🇷
Fundacao Universitaria de Cardiologia - Instituto de Cardiol, Porto Alegre, Rio Grande do Sul, Brazil
🇧🇷
InCor, Sao Paulo, Brazil

and more 32 locations

Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Phase 4

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection

First Posted Date: 2011-11-09

Last Posted Date: 2017-02-06

Lead Sponsor: CSL Behring

Target Recruit Count: 46

Registration Number: NCT01467947

Locations: 🇧🇬
MHAT "Tsaritsa Yoanna", Sofia, Bulgaria
🇭🇺
Semmelweis University, Budapest, Hungary
🇵🇱
Jagiellonian University, Krakow, Poland

and more 1 locations

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Phase 3

Completed

Conditions: Primary Immune Deficiency

Interventions: Biological: Immune globulin subcutaneous (Human)

First Posted Date: 2011-10-27

Last Posted Date: 2014-12-02

Lead Sponsor: CSL Behring

Target Recruit Count: 22

Registration Number: NCT01461018

Locations: 🇯🇵
Study site, Bunkyo-ku, Tokyo Metropolitan, Japan
🇯🇵
Study Site, Sapporo city, Hokkaido, Japan

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Phase 3

Completed

Conditions: Primary Immune Deficiency Disorder

Interventions: Biological: Immune globulin subcutaneous (Human)

First Posted Date: 2011-10-24

Last Posted Date: 2013-04-09

Lead Sponsor: CSL Behring

Target Recruit Count: 23

Registration Number: NCT01458171

Locations: 🇯🇵
Study site, Bunkyo-ku, Tokyo Metropolitan, Japan

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

Phase 3

Terminated

Conditions: Hemophilia A

Interventions: Biological: Biostate

First Posted Date: 2011-10-03

Last Posted Date: 2017-10-03

Lead Sponsor: CSL Behring

Target Recruit Count: 1

Registration Number: NCT01445197

Locations: 🇷🇺
Study Site, Barnaul, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy